NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/20/2026 12:49
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization15.38 mln
Float1.20 mln
Earnings Date08/13/2026
Piotroski F-Score
5
/ 9
Neutral
1-Year Forecast
28.50
Transformational upside
Relative Strength
35
/ 100
Underperforming
Debt / Equity
0.05
Debt-free
ROE
-124
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Akari Therapeutics Plc is a Boston-based cancer research company focused on creating a new class of precision medicines designed to destroy tumor cells while activating the body's own immune system. Its most advanced program, AKTX-101, targets a protein commonly found on solid tumors ? including those of the lung, breast, colon, and prostate ? by delivering specialized cell-killing agents directly to cancer tissue. The company is also advancing AKTX-102, a dual-targeting treatment, alongside additional compounds engineered to interfere with how cancer cells copy and repair their DNA. Together, these programs reflect Akari's broader strategy of building a pipeline of highly targeted therapies that attack cancer through multiple biological pathways.
